The FDA on July 10, 2018 granted accelerated approval to YERVOY® (Ipilimumab), for use in combination with OPDIVO® (Nivolumab), for the treatment of patients 12 years of age and older with MicroSatellite Instability-High (MSI-H) or MisMatch Repair deficient (dMMR) metastatic Colorectal Cancer (mCRC), that has progressed following treatment with a Fluoropyrimidine, Oxaliplatin, and Irinotecan. YERVOY® and OPDIVO® are products of Bristol-Myers Squibb Company Inc.
Bottom Ad
Advertisement
Subscribe
